FDA Reports Improvement in Postmarket Drug Oversight - - BioPharm International

ADVERTISEMENT

FDA Reports Improvement in Postmarket Drug Oversight



FDA has detailed, in a new report, the agency’s objective to give postmarket drug-safety monitoring the same priority as premarket drug review. According to an FDA press release, the “strengthened and modernized postmarket drug program has resulted in a substantial improvement in…oversight of drugs once they reach the American public.” The report “Advances in FDA’s Safety Program for Marketed Drugs,” released on Apr. 21, 2012, gives an overview of FDA tools and capabilities used in the monitoring of postmarket drug safety. According to the report, drug-safety information is being communicated to the public faster than it has in the past, with the Center for Drug Evaluation and Research (CDER) issuing 68 drug-safety communications in 2011 compared to 39 in 2010.

In 2004, CDER introduced the new drug-safety plan, which was enhanced by the Food and Drug Administration Amendments Act (FDAAA) of 2007. FDAAA authorized changes to the safety monitoring of postmarket drugs and gave FDA the authority to require postmarket studies of drug-safety concerns and drug-labeling changes.

Since 2008, FDA’s postmarket monitoring program has required 65 safety-related labeling changes and has required manufacturers to implement risk evaluation and mitigation strategies. CDER has increased staff, established specific safety positions within new drug application divisions, and created the new Office of Biostatistics, which focuses on postmarket drug safety. FDA has also created drug-monitoring programs such as Safety First, Sentinel, and Safe Use. The Mini-Sentinel pilot project has enabled FDA to utilize access to electronic healthcare information nationwide.

“Our oversight of the safety of marketed drugs has changed significantly over the past few years,” said Janet Woodcock, MD, director CDER, in the press release. “This report shows that the quality, accountability, and timeliness of postmarket drug safety decisions have been enhanced, and our public communication of this information is more effective.”

See related articles:

FDA Updates Sentinel Initiative Status (ePT)

FDA Seeks More Timely Drug Information Electronically (BioPharm International)

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here